Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 exploratory study in adult subjects with childhood onset fluency disorder.


Clinical Trial Description

At the Baseline visit, eligible subjects will be randomized 1:1 to receive either a target steady-state dose of ecopipam HCl ~2 mg/kg/day or matching placebo for a 12-week Treatment Period consisting of a 4-week Titration Phase followed by an 8-week Maintenance Phase. Subjects will return to the clinic at 4, 8, and 12 weeks after Randomization and Follow-up visits 7 and 14 days after completing the Treatment Period or Early Discontinuation. Efficacy assessments will be conducted at Weeks 4, 8, and 12 and safety assessments will be conducted at all visits. Subjects will have adverse events and other safety parameters assessed by phone or video conference at Weeks 2, 6 and 10 and 30 days after the last study drug administration. Signs or symptoms of withdrawal, abuse, and dependence will be monitored throughout the study. At the end of the Treatment Period or Early Discontinuation, subjects will taper study drug by 25 mg/day until off study drug, for up to 1 week. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04492956
Study type Interventional
Source Emalex Biosciences Inc.
Contact
Status Completed
Phase Phase 2
Start date October 2, 2020
Completion date April 4, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05641701 - Stimulation of the Thalamus to Ameliorate Persistent Disfluency N/A